Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
- DOI
- 10.1016/j.lungcan.2026.108906
- Published
- 2026-03
- Container
- Lung Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.lungcan.2026.108906,
title = {Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)},
author = {Omar Abdel-Rahman and Paul Taylor and Mary O’Brien and Jo Raskin and Claudio Dazzi and Veerle Surmont and Sabrina Zonato and Robin Young and Anne-Claire Toffart and Petra Jankowska and Adam Hassani and Sandrine Marreaud and Luc Boone and Sanjay Popat},
year = {2026},
journal = {Lung Cancer},
doi = {10.1016/j.lungcan.2026.108906},
url = {https://doi.org/10.1016/j.lungcan.2026.108906}
}RIS
TY - JOUR TI - Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG) AU - Omar Abdel-Rahman AU - Paul Taylor AU - Mary O’Brien AU - Jo Raskin AU - Claudio Dazzi AU - Veerle Surmont AU - Sabrina Zonato AU - Robin Young AU - Anne-Claire Toffart AU - Petra Jankowska AU - Adam Hassani AU - Sandrine Marreaud AU - Luc Boone AU - Sanjay Popat PY - 2026 JO - Lung Cancer DO - 10.1016/j.lungcan.2026.108906 UR - https://doi.org/10.1016/j.lungcan.2026.108906 ER -
APA
Abdel-Rahman, O., Taylor, P., O’Brien, M., Raskin, J., Dazzi, C., Surmont, V., Zonato, S., Young, R., Toffart, A., Jankowska, P., Hassani, A., Marreaud, S., Boone, L., & Popat, S. (2026). Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG). Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.108906
Source records
- crossref · retrieved 2026-09-25T23:47:06.058Z